Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc., a pioneering biotechnology company based in the United States, focuses on developing innovative therapies for immune-mediated diseases. Founded in 2011, Aldeyra has made significant strides in the field of ocular and systemic diseases, particularly through its unique approach to harnessing the power of the immune system. The company’s flagship products, including reproxalap, target unmet medical needs in conditions such as dry eye disease and allergic conjunctivitis, setting them apart with their novel mechanisms of action. Aldeyra's commitment to advancing therapeutic options has positioned it as a notable player in the biotechnology industry, with a growing portfolio of clinical-stage assets and a strong emphasis on research and development.
DitchCarbon Score
How does Aldeyra Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aldeyra Therapeutics, Inc.'s score of 25 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aldeyra Therapeutics, Inc.'s reported carbon emissions
Aldeyra Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Consequently, there are no documented reduction targets or climate commitments available from the company. As of now, Aldeyra Therapeutics has not established any science-based targets or climate pledges, nor does it inherit emissions data from a parent company. This lack of publicly available information suggests that the company may still be in the early stages of developing its climate strategy and emissions reporting framework. In the context of the biopharmaceutical industry, it is increasingly important for companies to adopt transparent climate commitments and reduction initiatives to align with global sustainability goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aldeyra Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
